Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Small Infants: A Randomized, Double-Blind Comparative Study
Open Access
- 1 October 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Tropical Pediatrics
- Vol. 53 (5) , 303-307
Abstract
Hepatitis B infection is very common in infants, especially in countries with limited resources. Hepatitis B vaccination is recommended in the routine immunization schedules in many countries, including India. We compared immunogenicity and reactogenicity of two recombinant hepatitis B (HB) vaccines in healthy infants. A total of 262 evaluable Indian infants received three doses of 10 μg of an Indian (GeneVac-B®) or European (Engerix-B®) HB vaccine in a double-blind, randomized fashion. The first dose, given at birth, was followed by a dose at age 6 and 14 weeks. All the subjects were initially seronegative for HB surface antigen (HBsAg) and anti-HB antibodies (anti-HBs). The post-vaccination anti-HBs titers were assessed by ELISA at the time of second and third dose, and 1 month after the third dose. Seroconversion and seroprotection were defined as anti-HBs titers ≥1 mIU/ml and ≥10 mIU/ml, respectively. After first dose, the seroconversion rates were 20% and 17%, in Indian and European vaccine recipients, respectively. The second and third dose increased the seroconversion to 84% and 80%, and to 98% and 98%, respectively. Correspondingly, the seroprotection rates after the first dose was 11% and 10%, and consequently 54% and 58%, and 97% and 95%. None of the differences between vaccines reached statistically significant proportions. Geometric Mean Titer after third dose was 383 mIU/ml and 285 mIU/ml, respectively, also this difference remaining insignificant. Adverse events were similar in both vaccine groups. Immunogenicity and reactogenicity of the Indian and European Hepatitis B vaccines were comparable, when immunization was started at birth.Keywords
This publication has 11 references indexed in Scilit:
- Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adultsVaccine, 2006
- A mathematical model to estimate global hepatitis B disease burden and vaccination impactInternational Journal of Epidemiology, 2005
- EVALUATION OF IMMUNOGENICITY AND SAFETY OF GENEVAC B: A NEW RECOMBINANT HEPATITIS B VACCINE IN COMPARISON WITH ENGERIX B AND SHANVAC B IN HEALTHY ADULTSIndian Journal of Medical Microbiology, 2004
- Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov modelJournal of Hepatology, 2003
- Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in ThailandVaccine, 2002
- Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infantsJournal of Medical Virology, 2002
- Association Between Administration of Hepatitis B Vaccine at Birth and Completion of the Hepatitis B and 4:3:1:3 Vaccine SeriesJAMA, 2000
- Seroepidemiologic Survey for Hepatitis B Virus Infection in Taiwan: The Effect of Hepatitis B Mass ImmunizationThe Journal of Infectious Diseases, 1999
- Simultaneous administration of Hepatitis B vaccine with other E.P.I. vaccinesIndian Journal of Pediatrics, 1994
- Comparative evaluation of the immunogenicity of yeast‐derived (recombinant) and plasma‐derived hepatitis B vaccine in infantsJournal of Medical Virology, 1991